5Nathan D M. Long-term complications of diabetes mellitus[J]. N Engl J Meg, 1993, 328(23) : 1676-1681.
6Gabbay K H. The sorbitol pathway and the complications of diabetes[J]. N Eagl J Meg, 1973, 288(16) : 831-836.
7Jaspan J B, Towle V L. Clinical studies with an aldose reduc-tase inhibitor in the autonomic and somatic neuropathies of di-abetes[J]. Metabolism, 1986, 35(Suppl, 1): 83-92.
8Foppiano M, Lombardo G. Worldwide pharmacovigiiance systems and tolrestat withdrawal[J]. Lancet, 1997, 349(9049): 399-400.
9Greene D, Arezzo J, Brown M. Dose-related effects of the aldose reductase inhibitor zenarestat on nerve sorbitol levels,nerve conduction velocity and nerve fiber density in human diabetic neuropathy[J]. Diabetes, 1996, 45(Suppl, 2): 9-12.
10Oates P J, Ellerly C A. Reversal of galactose-induced renal hyperperfusion in rats by aldose reductase inhibitor zopolre-stat[J]. Diabetologia, 1999, 42(Suppl, 1): Abst 1034.
